VVA HURTS TOO MANY WOMEN
And some of them may be your patients. However, only approximately 50% of menopausal women with VVA discuss VVA symptoms with their healthcare provider (HCP).1
Women may spend, on average, more than one-third of their lives in a hypoestrogenic state. 7
CONSIDER JUST HOW PAINFUL VVA CAN BE
VVA can cause a variety of unpleasant symptoms that may not resolve without treatment, including1-5,7-8:
THE NUMBERS MAKE A PAINFUL POINT
VVA: A PRICKLY ISSUE FOR BODY, MIND, AND SPIRIT
TOO MANY WOMEN ARE SUFFERING IN SILENCE
Are any of your patients experiencing the Very Very Awful symptoms of VVA? Asking just one more question could change everything.
Menopause, it doesn't have to hurt.
Click below to view ACOG and NAMS position statements
Thank you for requesting more information from TherapeuticsMD. Your information has been received.
We’re sorry, but there was a problem processing your request. Please try again. If the problem persists, please Contact Us .
TherapeuticsMD, Inc. is an innovative women’s healthcare company exclusively focused on developing and commercializing products for women throughout their life cycles.
References: 1. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-1799. 2. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. 3. Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. Clin Med Insights Reprod Health. 2014;8:23-30. 4. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068. 5. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902. 6. IMS SDI’s Total Patient Tracker; Annual 2016. 7. Chapter 1: overview of menopause. Menopause.org. http://www.menopause.org/docs/2012/cg_a.pdf?sfvrsn. Accessed September 6, 2016. 8. Chen L, Ng M, van der Vlugt MH, et al. Statistical Considerations for the Efficacy Assessment of Clinical Studies of Vulvar and Vaginal Atrophy. Therapeutic Innovation & Regulatory Science. 2010;44(5):581-588. 9. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The women's EMPOWER survey: identifying women's perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14(3):413-424. 10. Simon J, Kokot-Kierepa M, Goldstein J, Nappi R. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause. 2013; 20(10):1043-1048.